Tradestie Institutional Equity Comparison Engine

ZBIO vs ABCL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus ABCL at 27.6x Forward P/E and -1550.0% operating margin (-76.3% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against ABCL sits in CONSOLIDATION (29th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
ZBIO N/M vs ABCL 27.6x Fwd P/E
Growth & Margin Winner ABCL
Op Margin -2747.5% vs -1550.0% ยท YoY -100.0% vs -76.3%
Momentum & Technical Winner ABCL
1Y -21.7% vs +207.2% ยท 52W Pos 46% vs 68%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs CONSOLIDATION (29th %ile IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.12
-3.22% 1D
Market Cap $3.8B
1M Return -5.76%
1Y Return +207.18%
Forward P/E 27.6x
Unified AI Score
63.3 / 100 BUY
Tech 57.0 Fund 58.0 Flow 67.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% ABCL +207.18% Spread: +228.86 pp (ABCL Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ZBIO Revenue ABCL Revenue ZBIO Op. Margin ABCL Op. Margin Margin Edge
FY2019 N/A $10M N/A -35.5% ABCL
FY2020 N/A $230M N/A 66.9% ABCL
FY2021 N/A $380M N/A 54.5% ABCL
FY2022 N/A $490M N/A 44.6% ABCL
FY2023 $50M $40M -74.3% -623.8% ZBIO
FY2024 $10M $30M -3277.8% -1091.7% ABCL
FY2025 $10M $80M -3830.6% -289.0% ABCL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (2) vs ABCL (8)
Institutional Metric ZBIO ABCL Criterion Row Winner
Market Capitalization Scale $1.9B $3.8B Larger Scale ABCL
Trailing P/E Ratio Valuation N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio Valuation N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY) Growth -100.0% -76.3% Higher Growth ABCL
Operating Margin (TTM) Profitability -2747.5% -1550.0% Higher Margin ABCL
Net Profit Margin Profitability 0.0% -248.8% Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency -265.1% -17.3% Higher ROE ABCL
52-Week Range Position Momentum 46% ($14โ€“$45) 68% ($3โ€“$15) Stronger Trend ABCL
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 2.30ฮฒ ยท 87% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 63.3 / 100 (BUY) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs ABCL Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABCL CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 29th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor ABCL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.